Series A rounds in Biotech have significantly increased

As expected, the top US Series A rounds in Biotech substantially outperformed the top European rounds. In 2020, the average ticket size of the top 10 Series A deals in Biotech (by ticket size) in the U.S. is twice that of Europe. The largest Series A Biotech deal in Europe was closed by Arvelle Therapeutics at EUR 205m. In contrast, the largest deal in the U.S. was EUR 287m by RBNC Therapeutics.

The average ticket size of the top 10 Series A deals in Biotech has significantly increased over the last 5 years. Compared to 2016, the average ticket size in Europe increased by roughly 150% while the ticket size in the U.S. increased by 46%. 

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here:

[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]